# Crescent Biopharma, Inc. (CBIO)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/crescent-biopharma-inc/ JSON: https://steadybase.io/company/crescent-biopharma-inc.json Checked Nov 10, 2026. Latest filing read: Sep 18, 2026.

## Company

- Legal name: CRESCENT BIOPHARMA, INC.
- Ticker: CBIO (Nasdaq)
- SEC CIK: 0001253689
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Waltham, MA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: crescentbiopharma.com
- Investor relations: https://investors.crescentbiopharma.com/events-presentations
- LinkedIn: https://www.linkedin.com/company/crescent-biopharma
- Next earnings date: Nov 14, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $10.8M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/0001628280-26-011983-index.html
- Operating income: -$152.6M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/0001628280-26-011983-index.html
- Net income: -$153.9M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/0001628280-26-011983-index.html
- SG&A: $25.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/0001628280-26-011983-index.html
- Employees: 44 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- Shares outstanding: 37,143,940 as of Jul 27, 2026 (10-Q filed Jul 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026050869/0001628280-26-050869-index.html
- Auditor: Pricewaterhousecoopers LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm

## Business

We were incorporated under the laws of the State of Delaware in 2003., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc. (“Pre-Merger Crescent”). Prior to the reverse recapitalization transaction, Pre-Merger Crescent was established and incorporated under the laws of the state of Delaware on September 19, 2024.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $10.8M | -$152.6M | -$153.9M | $25.4M |
| Dec 31, 2023 | $10,000 | -$39.3M | -$36.9M | $19.2M |
| Dec 31, 2022 | $75,000 | -$47.4M | -$46.7M | $19.1M |
| Dec 31, 2021 | $1.2M | -$63.4M | -$63.4M | $17.1M |
| Dec 31, 2020 | $10.2M | n/a | n/a | n/a |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/crescent-biopharma-inc.json

## Officers and directors

- Joshua T. Brumm, Chief Executive Officer. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026062701/0001628280-26-062701-index.htm
- Richard William Scalzo, Chief Financial Officer. LinkedIn: https://linkedin.com/in/rickscalzo. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026062705/0001628280-26-062705-index.htm
- Richard Scalzo, Chief Financial Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- Jonathan McNeill, President and COO. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026062700/0001628280-26-062700-index.htm
- Jonathan McNeill, M.D., Chief Operating Officer and President. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- Ellie Eunkyung Im, Chief Medical Officer. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026062706/0001628280-26-062706-index.htm
- Jan Pinkas, Chief Scientific Officer. LinkedIn: https://linkedin.com/in/jan-pinkas-2252ba10. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026062707/0001628280-26-062707-index.htm
- Ryan Lynch, Treasurer, Senior Vice President of Finance and Chief Accounting Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- Christopher Grant Doughty, Chief Business Officer. Source: Form 4 filed Dec 17, 2025, https://www.sec.gov/Archives/edgar/data/1253689/000162828025057685/0001628280-25-057685-index.htm
- Alexandra Balcom, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- David Lubner, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- Susan Moran, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm

## Recent 8-K events

- Oct 15, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/cbio-20261015.htm
- Jul 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/cbio-20260730.htm
- Jul 15, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026048347/cbio-20260714.htm
- Jul 14, 2026: Item 2.02, Results of operations and financial condition (earnings release). Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026048151/cbio-20260714.htm
- Jun 3, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/cbio-20260602.htm
- Apr 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/cbio-20260429.htm
- Feb 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011988/cbio-20260226.htm
- Dec 4, 2025: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/cbio-20251202.htm
- Nov 6, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/cbio-20251106.htm
- Jul 31, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828025036846/cbio-20250729.htm

## Insider trades (Form 4)

- Sep 18, 2026: Joshua T. Brumm (Chief Executive Officer) sold 9,447 shares, about $159,775. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026062701/0001628280-26-062701-index.htm
- Sep 18, 2026: Jonathan McNeill (President and COO) sold 4,570 shares, about $77,235. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026062700/0001628280-26-062700-index.htm
- Sep 16, 2026: Ryan Lynch (See Remarks) sold 240 shares, about $4,296. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026062709/0001628280-26-062709-index.htm
- Sep 16, 2026: Jan Pinkas (Chief Scientific Officer) sold 658 shares, about $11,778. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026062707/0001628280-26-062707-index.htm
- Sep 16, 2026: Ellie Eunkyung Im (Chief Medical Officer) sold 623 shares, about $11,152. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026062706/0001628280-26-062706-index.htm
- Sep 16, 2026: Richard William Scalzo (Chief Financial Officer) sold 568 shares, about $10,167. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026062705/0001628280-26-062705-index.htm
- Sep 16, 2026: Barbara Harlin Bispham (See Remarks) sold 620 shares, about $11,098. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026062703/0001628280-26-062703-index.htm
- Jul 16, 2026: Tomas Kiselak (Director) bought 853,450 shares, about $12.4M. Source: https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/0001104659-26-085113-index.htm
- Jul 16, 2026: Peter Evan Harwin (Director) bought 853,450 shares, about $12.4M. Source: https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/0001104659-26-085113-index.htm
- Jul 16, 2026: Healthcare Fund L.P. Fairmount II (Director) bought 853,450 shares, about $12.4M. Source: https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/0001104659-26-085113-index.htm
- Jul 16, 2026: Funds Management LLC Fairmount (Director) bought 853,450 shares, about $12.4M. Source: https://www.sec.gov/Archives/edgar/data/1253689/000110465926085113/0001104659-26-085113-index.htm
- Jun 22, 2026: Ryan Lynch (See Remarks) sold 465 shares, about $8,365. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026044893/0001628280-26-044893-index.htm
- Jun 22, 2026: Jan Pinkas (Chief Scientific Officer) sold 1,288 shares, about $23,171. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026044892/0001628280-26-044892-index.htm
- Jun 22, 2026: Richard William Scalzo (Chief Financial Officer) sold 1,112 shares, about $20,005. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026044890/0001628280-26-044890-index.htm
- Jun 22, 2026: Barbara Harlin Bispham (See Remarks) sold 1,218 shares, about $21,912. Source: https://www.sec.gov/Archives/edgar/data/1253689/000162828026044887/0001628280-26-044887-index.htm

## Latest filings

- 8-K filed Oct 15, 2026: https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/cbio-20261015.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- 10-Q filed Jul 30, 2026: https://www.sec.gov/Archives/edgar/data/1253689/000162828026050869/cbio-20260630.htm
- DEF 14A filed Apr 21, 2026: https://www.sec.gov/Archives/edgar/data/1253689/000162828026026282/cbio-20260421.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/